Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 20;16(9):2591–2604. doi: 10.1158/1078-0432.CCR-09-2443

Figure 2.

Figure 2

Doxorubicin (1.2mg/kg/biweekly) followed by TRAIL (10mg/kg, five days per week) decreases leiomyosarcoma (SKLMS1) growth in vivo. A) Tumor growth curves per treatment group (10mice/group); B) Representative MRI images of STS xenografts at time of treatment initiation and by the end of the study. Graphs depict average tumor volume as calculated from MRI images (n=3/group; *p<0.05). White bars represent tumor volume at treatment initiation and black bars at study termination; C) PCNA immunohistochemistry and TUNEL staining (red = nuclei, green =TUNEL) of SKLMS1 xenograft specimens (selected for presence of viable tumor shown in H+E); and, D) DR4 (green) and DR5 (red) immunoflorescent staining of SKLMS1 xenografts (nuclei are depicted in blue).